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Abstract
Background: To assess the effect of intravitreal triamcinolone acetonide (iTA) as an adjunctive treatment to
transpupillary therapy (TTT) for new subfoveal choroidal neovascular membranes (CNV) in age-related macular
degeneration (AMD).
Methods: This prospective randomized controlled pilot study comprised 26 patients scheduled to receive TTT,
due to either absent indications for photodynamic therapy or financial issues. Patients were assigned into; Group
A (n = 14) received TTT alone and Group B (n = 12) received iTA (4 mg) followed by TTT within one week.
Follow ups were at 2 weeks, and 1, 3 and 6 months for; best-corrected visual acuity (BCVA) by ETDRS chart at
4 meters, intraocular pressures (IOP), fluorescein angiography (FAG), and central foveal thickness by optical
coherence tomography (OCT).
Results: All 26 patients completed 6 months of follow ups. The average age for both groups was 74 years. Occult
CNV formed 64% and 41%; classis/predominately classic 21% and 16.6%; and minimally classic 15% and 42.4% of
group A and B respectively. At baseline; the mean BCVA was 0.045 for group A and 0.04 for group B; mean CNV
size was 6.15 disc diameter (DD) and 2.44 DD; mean OCT foveal thickness was 513 um and 411 um for group
A and B respectively with no statistical differences (P = 0.8, 0.07, and 0.19). At six months the proportion of
patients gained ≥ 1 lines was 14% and 25% (P = 0.136) and stabilization was 86% and 66% (P = 0.336); the mean
size of the CNV was 5.63 DD and 2.67 DD (P = 0.162); rate of CNV closure was 64% and 83% (P = 0.275); and
the mean OCT central foveal thickness was 516.36 um and 453.67 um (P = 0.341), for group A and B respectively.
Conclusion: The use of iTA as an adjunctive to TTT for new subfoveal CNV in AMD showed a tendency towards
better functional results. However due to the small sample size of the study a statistically significant results could
not be reached.
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Background
Age-related macular degeneration (AMD) is one of the
leading causes of blindness in the western world; with the
most common cause of visual loss is the formation of
choroidal neovascularization (CNV) [1]. Laser photoco-
agulation has been proven to be more effective than the
natural history of the disease process in both extra- and
juxtafoveal CNV [2,3]. Currently, photodynamic therapy
(PDT) with verteporfin and laser photocoagulation are
the only proven therapies for the subfoveal CNV [4-8].
PDT has been proven beneficial for patients with both
predominately classic CNV and with some benefits for
occult with no classic CNV [4,6]. A retrospective review of
1000 consecutive patients with CNV in AMD showed that
17.1% had predominantly classic CNV [9]. In addition,
analysis has shown that the treatment has minimal cost
effectiveness, which is principally due to the high cost of
the drug, the need of many retreatments, and the contin-
uing visual decline that most patients experience even
with re-treatments [10].
Transpupillary therapy (TTT) is a technique in which heat
is delivered to the choroid and retinal pigment epithelium
through the pupil using an 810-nm infrared diode laser.
The diode laser has theoretical advantages over other
wavelengths of light because there is little absorption in
the xanthophyll layer and thus damage to the nerve fiber
layer is minimized. Also, it is poorly absorbed by hemo-
globin allowing an improved ability to treat through pre-
retinal and subretinal hemorrhage [11]. The wavelength
of the diode laser is mainly absorbed by melanin at the
level of the choroid and retinal pigment epithelium, ena-
bling treatment of choroidal lesions [12]. TTT is also sig-
nificantly less expensive than PDT. It has been used to
treat choroidal melanomas, and in preliminary trials to
treat both classic and occult subfoveal CNV [13-17].
There is evidence suggesting that steroids may have a ben-
eficial effect in patients with CNV. Eyes with CNV have
histopathologic evidence of inflammation, and neovascu-
larization is a frequent component of inflammatory proc-
esses [18-20]. Histopathological examination of CNV
complexes has shown the presence of inflammatory cells
[18-20]. In addition the amount of vascular endothelial
growth factor (VEGF), the major cytokines involved in ini-
tiating angiogenesis, has been shown to be proportional
to the amount of inflammatory cells present [21]. Corti-
costeroids also have in addition a direct antiangiogenic
effects [22-25]. Triamcinolone acetonide and other ster-
oids have been shown to be effective in inhibiting neovas-
cularization in animal models [26,27]. Several clinical
studies have shown an apparent beneficial effect where
treated patients appeared to have a favorable effect on vis-
ual acuity and fundus appearance, although a significant
proportion of patients still lost vision [28-30].
It may be possible to treat patients with CNV with TTT
plus iTA, to combine the immediate effect of TTT with the
longer-lasting, anti-inflammatory and possibly synergistic
effect of intraocular triamcinolone. To help investigate
this possibility we started a randomized controlled pilot
study of combined TTT with iTA for CNV in patients with
AMD.
Methods
Although a randomized, multicenter, prospective, pla-
cebo-controlled trial (TTT4CNV, preliminary results,
ARVO 2005) is underway to investigate the value of TTT
in the treatment of occult subfoveal CNV, we did not find
any report in a medline search that evaluates the effect of
intravitreal triamcinolone with TTT for subfoveal CNV.
Considering recent reports that demonstrate beneficial
effects when triamcinolone is associated to PDT, we
decided to conduct a prospective randomized non-
masked clinical study of combined TTT with iTA in
patients with CNV secondary to AMD.
Approval for the study was obtained from the hospital's
ethical committee which is in compliance with the Hel-
sinki Declaration. All patients received a thorough expla-
nation of the study design and aims, and were provided
with written informed consent. Patients were seen at Aso-
ciación Para Evitar la Ceguera en Mexico, "Dr. Luis
Sanchez Bulnes Hospital", Mexico City, Mexico. All
patients had a baseline evaluation for the following:
- Best-Corrected Visual Acuity (BCVA) that was evaluated
using an ETDRS chart, measured with refraction obtained
at the beginning of the study and recorded as a decimal
equivalent value. Special careful was taken to avoid extra-
foveal fixation.
- Slit-lamp biomicroscopy
- Indirect ophthalmoscopy
- Flourescein angiography (FAG)
- Optical Coherence Tomography (OCT) measurement of
central foveal thickness.
Eligibility criteria includes: 55 years or older, new CNV
under the geometeric center of the fovea, and VA of <0.20.
No restriction to the type of the membrane (classic, pre-
dominately classic, or occult) was made. The patient had
to have a clear media and the ability and willingness to
understand the informed consent. Patients were excluded
if they had received previous treatment, have any condi-BMC Ophthalmology 2005, 5:27 http://www.biomedcentral.com/1471-2415/5/27
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tion other than AMD to account for the CNV or refuse fol-
low up. Patients could not have pre-existing atrophy of
the fovea or a rip of the retinal pigment epithelium (RPE).
Patients were also excluded if they were using corticoster-
oids. They could not have any disease that would
interefere with the treatment, increased risk of side effects,
or been confused with side effects of the treatment (as
anticoagulant treatment, hepatitis, prophyria, uncon-
trolled glaucoma, or sensitivity ot the drug or the floures-
cein dye used in the trial). Only one eye per patient was
entered in the study.
Once the patients accepted to be part of the study, were
randomly assigned by an unmasked investigator (RA)
using a random number table, to one of two groups:
Group A received transpupillary thermotherapy (TTT)
alone, and Group B received TTT within a week of intrav-
itreal triamcinolone acetonide injection (iTA). Same
investigator (RA) treated the patients, knowing the
assigned group before to apply TTT or inject iTA.
Transpupillary therapy
Transpupillary thermotherapy was delivered through a slit
lamp using a modified infrared diode laser at 810 nm
with an adjustable beam width of 1.2 mm, 2.0 mm, 3.0
mm and 4.3 mm (Iris Medical Instruments, Mountain
View, CA). The treatment parameter was adjusted accord-
ing to the CNV type and size. Topical 0.5% proparacaine
was applied before placement of a three mirror Gold-
mann lens coated for use with the diode laser. Continues
observation through the slit lamp ensured fixation. Treat-
ment was initiated with one spot for 60 seconds' duration
at a power setting ranging between 360 and 880 mW such
that no visible change or a barely detectable light-gray
appearance to the lesion was present at the end of the
treatment. Power settings was proportional to the spot
size with larger spots requiring higher energy levels. In
general, for a 2-mm spot size, the initial power level was
between 360 mW and 700 mW. The spot size was adjusted
to be 500 um larger than the membranes' greater diame-
ter, if the CNV is larger than 4300 um, then overlapping
spots were used. If any retinal whitening was observed or
patient felt any pain, the power of the laser was decreased
by 100 mW. Treatment was re-initiated and if retinal whit-
ening continued to be observed, the power setting was
again decreased by 100 mW. Care was taken to ensure that
the entire lesion border was covered with treatment beam.
Intravitreal triamcinolone injection
Intravitreal triamcinolone acetonide were given as fol-
lows: patients received several drops of topical propa-
racaine and one drop of Betadine 5% solution (Purdue
Pharma, L.P., Stamford, CT). They were given then topical
flouroquinolone drops once every 5 minutes for 30 min-
utes. A wire speculum was inserted in the eye. The patient
A 65 year old patient with visual acuity of 1/10 in right eye  that developed visual lost three months earlier Figure 1
A 65 year old patient with visual acuity of 1/10 in right eye 
that developed visual lost three months earlier. Color photo-
graph shows a CNV with a small hemorrhage and sub retinal 
fluid. Fluorescein angiogram shows A: Early RPE defects 
above and below the foveal center. Later B: shows late dye 
leakage indication occult CNV.BMC Ophthalmology 2005, 5:27 http://www.biomedcentral.com/1471-2415/5/27
Page 4 of 7
(page number not for citation purposes)
reclined slightly and was instructed to look up. An injec-
tion of 0.1 cc triamcinolone (Kenalog 40 mg/ml, Bristol
Myers Squibb, New York, NY) was given at the 6-o'clock
postion 3.5 to 4 mm posterior to the limbus using a 27
gauge needle. During the injection the needle was inserted
3 to 4 mm into the eye. The intraocular pressure was
measured 5 minutes afterwards. If the IOP exceeded 24
mmHg at any time during follow ups, patients were given
topical medications. If IOP exceeds 40 mmHg an anterior
chamber paracentesis using a 30-gauge needle to remove
0.1 cc of aqueous humor was performed.
Follow ups
Patients were give topical antibiotics to use four times per
day for one week. Patients were seen in follow ups at 2
weeks, and 1,3 and 6 months after the treament. At each
follow up visit, they had BCVA measurement, slit lamp
biomicroscopy, intraocular pressure measurement (IOP),
and indirect ophthalmoloscopy. FAG, and OCT measure-
ment of foveal center were done at 3 and 6 months.
Retreatment was performed using the same protocol if
there was no change in subretinal elevation by clinical
examination and OCT, together with persistent leakage on
FAG at 3 and 6 months.
Outcome measures
Primary outcomes were BCVA, CNV size and rate of clo-
sure, and OCT measurements at the foveal center. Main
secondary outcome was retreatment rates.
Results
There were 26 eyes of 26 patients enrolled in our study.
The mean age was 74 years for both groups with no statis-
tical difference in the age of the patients or other demo-
graphic data (Table 1) between the two groups. Baseline
mean BCVA were 0.045 and 0.04 in groups A and B
respectively, with no statistical significant difference (P =
0.885 Mann-Whitney). In group A there were 64% (9/14)
occult CNV, 21% (4/14) classic/predominately classic
CNV, and 15% (1/14) minimally classic CNV. In group B
there were 41% (5/12) occult CNV, 16.6% (2/12) classic/
predominately classic CNV and 16.6% (2/12) minimally
classic CNV, 3 patients was undetermined. The break-
down of the type of the CNV showed no statistical differ-
ence between both groups (P = 0.095 Mann-Whitney).
The mean CNV size at baseline was 6.15 disc diameter
(DD) and 2.44 DD for group A and B respectively (P =
0.075 Mann-Whitney). The mean OCT foveal thickness
was 513 um and 411 um for group A and B respectively at
baseline with no statistical significant different (P = 0.190
Mann-Whitney).
Six-month data
The six months follow up was available for all 26 patients.
Media BCVA was 0.045 for both groups. The proportion
Patient in figure 1, four months after TTT and iTA Figure 2
Patient in figure 1, four months after TTT and iTA. Color 
photograph shows absence of sub retinal fluid and hemor-
rhage. Fluorescein angiography shows in (A) a large area of 
RPE and choroidal atrophy with (B) late staining of the 
enlarged chorioretinal scar after treatment with no evidence 
of dye leakage.BMC Ophthalmology 2005, 5:27 http://www.biomedcentral.com/1471-2415/5/27
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of patients gained ≥ 1 lines was 14% (1/14) and 25% (2/
12) for group A and B respectively (P = 0.336 Wilcoxon
test), and stabilized in 86% (12/14) and 66% (8/12) of
patients in group A and B respectively (P = 0.26 Wilcoxon
test) both of which were not statistically significant. The
mean size of the CNV was 5.63 DD and 2.67 DD for
patients in group A and B respectively (P = 0.162 Mann-
Whitney). Rate of CNV closure was 64% (9/14) and 83%
(10/12) for group A and B respectively at six months (P =
0.275 Chi Square). The proportion of patients with sub-
retinal fluids was 60% and 50% with the mean OCT cen-
tral foveal thickness was 516.36 um and 453.67 um, for
groups A and B respectively (P = 0.341 Mann-Whitney).
All the above mentioned data were not statistically signif-
icant when compared to baseline and between both
groups.
Occult CNV had more lines gain, where 60% (3/5) of
patients receiving iTA showed lines gain compared with
22% (2/9) of patients not receiving iTA. Also patients with
occult CNV had a relatively better response to iTA than
classic membranes where 66% of patients without iTA
showed lines gain compared with 80% of patients with
iTA. The retreatments rate was 36% and 17% for groups A
and B respectively (P = 0.175 Chi Square).
Complications
No patient had evidence of endophthalmitis at any time
point. An increase in intraocular pressure beyond 23
mmHg was experienced in 2 patients in group B, who did
not have previous glaucoma. Intraocular pressure was
controlled with topical medication using beta blockers in
both patients. Mean IOP at baseline was 15.1 and 16.3
mmHg, and at six months was 15.0 and 16.3 mmHg for
groups A and B respectively. However two weeks after tri-
amcinolone injection the mean IOP in group B was 17.9
mm Hg. The lens status was not graded in this study by a
formalized method such as the Lens Opacities Classifica-
tion System (LOCS II) [31]. However progression of
nuclear sclerosis was not seen in any patient.
Discussion
This single-center prospective comparative randomized
pilot study examined the use of combined TTT with iTA
for the treatment of CNV secondary to AMD. We found
that although there was no statistical significant difference
in the functional result between both groups there was a
trend in favor of the combined TTT with iTA. Patients
receiving iTA with TTT had more line gains at six months,
than those that did not receive iTA. In addition there was
less retreatment in patients in the iTA group, than in the
other group. However the anatomical results were clini-
cally and statistically insignificant, in terms of the final
size of the CNV, and OCT central foveal thickness.
Although exudative AMD is the leading cause of visual
loss in patients above 60 years in western countries, con-
ventional PDT with verteporfin can be given as a treat-
ment in a minority of those with the disease [1]. In
addition patients with CNV require multiple retreatments.
The proportion requiring retreatments at the first 3-
month interval is 90.8% for the TAP study and 68.9% for
the VIP study [4-6]. In addition, PDT has minimal cost
effectiveness as shown by previous studies [10]. TTT on
the other hand is significantly less expensive than PDT
and its energy penetrate deep to the choroid and RPE with
minimal absorption by neurosensorial retina. The energy
is eliminated like heat causing an elevation of local tem-
perature (15–20 degree Celsius) inducing apoptosis with
thermal inhibition of angiogenesis and vascular thrombo-
sis [14,15]. TTT in preliminary trials showed benefits in
treating both classic and occult subfoveal CNV [14-17].
There are several possible reasons to combine TTT with
iTA. Choroidal neovascularization have other constitu-
ents such as inflammatory cells, and other signs of inflam-
mation that might not benefit from the short term
angiogenic effect of TTT [18-20]. Corticosteroids have a
direct antiangiogenic effects [22-25]. And have been
shown to be effective in inhibiting neovascularization in
animal models [26-28]. Steroids can modulate the pro-
duction of and reduce the permeability increased by
VEGF. These secondary effects would not be expected to
occur with TTT alone. Intravitreal TA persists in the vitre-
ous cavity which extends the duration of treatment against
the neovascular complex [32,33]. Several clinical studies
have shown an apparent beneficial effect where treated
patients appeared to have a favorable effect on visual acu-
ity and fundus appearance, although a significant propor-
tion of patients still lost vision [29-31].
In his pilot study, Reichel et al had 16 patients with occult
subfoveal CNV treated with TTT with 12 months of follow
ups [14]. Visual acuity improved 2 or more lines in 19%,
stabilized in 56%, the exudation decreased in 94% of
patients, and 19% of cases had to be re-treated. Other
authors described improvements of 2 or more lines
between 12.4 to 30% of cases, and VA stabilization
between 40 to 43%, exudation reduction was around 75%
and approximately 25% of patients required re-treatment
[15-19]. In our study we obtained 14% and 25% VA
improvement of one or more lines for group A and B
respectively. However the little number of patients did not
permit us to establish a statistical difference between
groups, but our results are comparable to those reported
in the literature. Also results of stabilization of VA, which
was 86% and 66.6% of patients in group A and B respec-
tively, was consistent with previous reports. We believed
that these results must to be considered in the context of
patients with very low VA, so excessive diminution wasBMC Ophthalmology 2005, 5:27 http://www.biomedcentral.com/1471-2415/5/27
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difficult, also many patients were considered out of thera-
peutical limits due to big size of membrane and bad VA,
even though we could obtain improvement from baseline
visual acuity.
Complications arising from this treatment may be
expected to include all of those that could occur from TTT
therapy as well as the incremental risks posed by the intra-
vitreal injection of triamcinolone. The additional risks are
principally increased IOP, progression of cataract forma-
tion, and endophthalmitis. In the present study we have
increased IOP in 2 patients in group B, both of which were
controlled by medications and resolved completely in 3–
4 months after treatment. Progression of cataract and
endophthalmitis were not seen in our study group.
This study is limited by the small number of patients in
each group with a limited follow ups. The physicians were
not blinded during examination of the patients or FAG.
The patients also knew they were in an experimental
study. Therefore finding from this study should not be
used as a justification to treat patients in an uncontrolled
fashion. However in the course of development of new
treatment strategies, the iteration starts with pilot series
data that are used to formulate larger better controlled,
but more expensive studies.
Conclusion
The findings from this study suggest that the combination
of transpupillary thermotherapy along with intravitreal
triamcinolone offers the possibility of better functional
results than with TTT alone, meriting additional rand-
omized study.
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